Opinion|Videos|December 18, 2024
FCS’ Affect on Quality of Life
Key Takeaways
- Delayed FCS diagnosis can lead to exacerbated cardiovascular and metabolic consequences, increasing atherosclerosis and cardiovascular disease risk.
- Persistent hypertriglyceridemia from untreated FCS may result in chronic pancreatitis, diabetes, and liver disease.
Panelists discuss how familial chylomicronemia syndrome (FCS) affects patients’ quality of life, particularly in terms of their emotional well-being, employment burden, and social isolation due to recurrent acute pancreatitis, and explore the significant economic burden it places on patients and their families.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How does FCS affect patients’ quality of life (eg, their emotional well-being, employment burden, and social isolation), specifically regarding acute pancreatitis?
- What economic burden does FCS have on patients with acute pancreatitis and their families?
- What economic burden does FCS have on patients with acute pancreatitis and their families?
Advertisement
Related to this article
A propensity-matched TriNetX analysis presented at ACG 2026 found lower MACE and mortality with resmetirom vs semaglutide over 2 years in MASLD/MASH.
Volixibat reduced itch scores vs placebo in patients with PSC and moderate to severe pruritus in the phase 2b VISTAS trial presented at ACG 2026.
Topline phase 3 ALOFT-IPF data show admilparant 60 mg improved 52-week FVC vs placebo in IPF, while the 120 mg dose missed statistical significance.
Post hoc FORTIFY OLE analyses presented at ACG 2026 show sustained remission across disease locations and rising no-draining-fistula rates over 5 years.
Topline data show a 69% placebo-adjusted drop in serum bile acids, with an sNDA planned for the first half of 2027.
Jennifer Hsiao, MD, discusses HS treatment expectations, biologic selection, oral JAK inhibitors, and comorbidity screening.
Phase 3 extension shows oral denifanstat sustains acne lesion reductions through 52 weeks, with 57% IGA success and 77% fewer inflammatory lesions.
Raj Chovatiya, MD, PhD, discusses biologic choice in atopic dermatitis, pipeline strategies, and remibrutinib’s approval for symptomatic dermographism.
Advertisement
Advertisement
Trending on HCPLive
1
GLP-1 Initiation in Heart Failure Reduces Pulmonary Artery Pressure, Hospitalizations
2
Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD
3
Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism
4
ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point
5